Italian clinical-stage precision oncology and radiotherapeutics company developing YntraDose, an image-guided, intratumoral delivery platform that injects Yttrium-90 beta-emitting microspheres into solid tumors
Italian clinical-stage precision oncology and radiotherapeutics company developing YntraDose, an image-guided, intratumoral delivery platform that injects Yttrium-90 beta-emitting microspheres into solid tumors. Its lead program targets locally advanced pancreatic cancer and is designed to provide durable local tumor control while complementing systemic therapies.